home > ict > spring 2010 > mena machine
International Clinical Trials

MENA Machine

Maha Al-Farhan at ClinArt International examines legal and regulatory authorities and research ethics committees in the Middle East and North Africa (MENA)

Although clinical trials have been conducted in the MENA region since the 1990s, recently there has been rapid development in the infrastructure of clinical trials. New international players are establishing offices throughout the region, indicating its increasing international profile, and at the same time there are more enquires from physicians for training, or to be considered as investigators in ongoing clinical trials. There are also frequent questions about conducting clinical trials in the region from major pharmaceutical companies and global CROs.


We conducted a survey across the region to gain precise, accurate and up-to-date information about active clinical research ethics committees (REC), regional regulatory authorities (RA), the most sought after therapeutic area, and the recommended investigators. Two surveys were constructed, one aimed at RECs and the other at RAs. The RECs questionnaire was composed of 10 sections:

  • General information – this section was aimed at updating our REC contact list, as well as obtaining official information about the history of the REC, recently approved clinical research protocols, the composition of the committee, and hospitals covered by the REC.
  • Standard operating procedures – this examined which phases of clinical trials are accepted for review, published SOPs, regulations, guidelines and membership status, such as Office for Human research Protections (OHRP) registration.
  • Study protocol submission procedure – this considered the application form, documents to be submitted, any applicable fees, meeting frequencies, interim reporting, safety reporting and the final report.
  • Clinical trials agreements (CTAs) – this section investigated the role of RECs in reviewing CTAs, as well as any recommended fee structure and cost of tests and procedure that should be taken into consideration when reviewing a CTA.
  • Vulnerable subjects – here we asked who the REC considers to be vulnerable subjects, such as paediatrics, women, the handicapped and prisoners.
  • Patient recruitment policy – we asked the REC about their procedure with regards to different patient recruitment methodologies, such as mass media advertising, online advertisement, posters and so on.
  • Experienced investigators – we inquired about the most experienced investigators and most active applicants of research proposals. This section helped us differentiate between key opinion leaders who are usually recommended by the sponsor’s sales department and good investigators who are eager to contribute to science.
  • Electronic case report forms – although the internet is largely available throughout the region, in some hospitals there may be limits to internet access and use of the hospital’s IT infrastructure. This question provided a good starting point to recommend sites and to list potential limitations at the study site selection stage.
  • Storage of investigational products – this helped us decide the suitability of study sites for any given study protocol. We asked about dedicated clinical trials storage areas and available fridges and freezers. We also asked about access control and the name of the pharmacist responsible for clinical trials.
  • Research centres – this section examined which research centres are available in some hospitals, taking into account that more hospitals are seriously considering the establishment of suitably dedicated research centres. We wanted to find out the maximum amount of information regarding these research centres.

The RA questionnaire is very similar to the regulatory questionnaire, but there were additional sections examining:

  • Applicable laws
  • Networks of REC
  • Investigational products importation

Table 1: The acceptance of different phases of clinical trials
according to country
Country Phase I Phase II Phase III  Phase IV 
UAE     X
Qatar      X
Kuwait     X X
Saudi Arabia   X
Lebanon X X X
Morocco     X


Twelve RAs responded to our questionnaire: Jordan, Lebanon, Kuwait, Qatar, Bahrain, the UAE, Oman, Saudi Arabia, Egypt, Tunisia, Morocco and Algeria, as well as over 90 RECs. It is worth noting that, initially, few respondents answered all questions in our questionnaire; however, having presented this data at meetings and conferences, we started receiving more spontaneous information. We treat the database as a live document, whereby we apply ongoing updates as new information becomes available to us. We plan to conduct at least one major annual review of all data included in order to ensure its validity.

Ninety-three committees responded to the questionnaire; we checked their OHRP status and we were pleasantly surprised to learn that almost half are registered. We questioned some of those that were not registered with the OHRP for the reason why, and the most common answer was that it was not mandatory. We also asked about their written SOPs, regulations and guidelines: while almost all of the committees stated that they have their own guidelines, only 37 supplied us with their written documents. All except three confirmed that they follow GCP guidelines, with the number of members ranging from 5 to 24. The largest National Ethics Committee is the Jordan Ministry of Health.

As for the submission procedure, all RAs and RECs accept submissions made by principal investigators, 23 would also accept submissions made by study sponsors and CROs, and two RAs and 14 RECs confirmed that they charge a fee that ranges from $500 to $3,000. It is a general requirement that clinical trial agreements and financial compensation are presented in the submission dossier of clinical trials. Often the REC questions the cost implication to the hospital overheads, 13 committees had actually decided a fee structure that includes the institute as well as the investigator. Fee per patients is also scrutinised in order to ensure that the clinical trial in consideration will not abuse hospital resources or implicate additional costs to the patient.

As for accepted practices of advertising for study subjects’ recruitment, nine committees have some sort of policy with regard to patient advertisement. The remaining committees do not have such a policy, but they generally agreed that it should be reviewed in order to avoid coercion.

We identified over 520 experienced clinical research investigators working in over 100 hospitals, with the most common approved clinical trials being in the areas of oncology, neurology, endocrinology, haematology, cardiovascular, respiratory, infectious diseases, gastrointestinal, and orthopaedic/rheumatology. We analysed about 100 hospitals that had participated in the survey to identify the most suitable clinical research sites. Our rating procedure was based on:

  • Research infrastructure
  • Number of experienced investigators
  • History of clinical trials
  • Size of the hospital

Table 2 summarises our findings, which are far from exhaustive. Some good sites were excluded from this list due to a lack of response from the hospital research offices.

Table 2: Highly rated clinical research centres in the MENA region    
Country Clinical Research Centre 1  Clinical Research Centre 2  Clinical Research Centre 3 
Jordan  King Hussein Cancer Centre  Jordan Hospital  Jordan Unviversity Hospital 
Lebanon  AUB Medical Centre Foundation  Hotel Deiu  Saint George Hospital 
Kuwait  Mubarak AlKabeer Hospital  AlAmiri Hospital  Dasman Center 
Qatar  Hamad Medical Hospital  AlAmal Hospital  Weill Cornell Medical College - and SIDRA 
Bahrain  Salmaniya Complex  Bahrain Defense Force Hospital   
UAE  Sheikh Khalifa Medical City  Tawam Hospital  Rashid Hospital 
Oman  Sultan Qaboos University Hospital  Royal Hospital  Nizwa Hospital 
Saudi Arabia  King Faisal Specialist Hospital  National Guard Hospital  King Saud/King Abdul Aziz University Hospital 
Egypt  Kiser El-Aini  AinShams University  Alexandria University 
Tunisia  Farahat Hatched University  Pasteur Institute  Institute of Salah Azaiez 
Morocco  Faculty of Medicine and Pharma at the University of Casablanca  Institute Pasteur du Maroc  Centre d'Oncologie Clinique le Littoral 
Algeria  Marie Curie Cancer Centre  MOH Hospitals   

Eleven committees stated that they routinely accept applications involving eCRFs, with appropriate restrictedaccess computer areas available. This is not to assume that the remaining hospitals do not accept eCRFs, rather it is an indication for further attention to be given to IT infrastructure when validating sites selected for eCRFs studies – for example, the provision of mobile internet connections and computers. Twenty-four committees stated that they were aware of a dedicated research department in their institute, and a similar number stated that all study medication was stored in specialised compartments in the main hospital pharmacy department under the supervision of a dedicated pharmacist.

Questions directed at RAs were similar to those asked of committees with the addition of a further section related to the importation of investigational product. In order to import study medication/investigational product, regional RAs were in unison in their requirements, stating that they need clinical trial approval and product details, such as name, LOT and batch number, expiry data, certificate of analysis, GMP certificate, certificate of origin, and a copy of the IP label in English and in Arabic. Since most countries in the MENA region do not accept applications for early-phase clinical trials (see Table 1); these regulatory authorities also requested marketing authorisation documents in the country of origin.


Our survey has established a road map for conducting clinical trials in the MENA region. We do recommend updating this information twice yearly as laws and regulations are being clarified continuously. It is very important for those planning their studies to have a full understanding of specific capabilities and challenges before considering the region.

The author would like to thank the ClinArt team for their contributions and suggestions, and Dr Antoinne Estephan, who inspired the idea of building a database of centres of clinical research excellence.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
Maha Al-Farhan is the chair of the Gulf Countries Chapter of the Association of Clinical Research Professionals (ACRP) – a US-based Association that aims to provide global leadership to promote integrity and excellence for the clinical research profession. Through the ACRP, Maha has coordinated and conducted numerous ACRP-certified training courses in the Gulf and Saudi Arabia, and is actively coordinating networking meetings and conferences. Maha is also a founding member of the first regional clinical research organisation in the MENA region, ClinArt International, where she works as the CEO.
Maha Al-Farhan
Print this page
Send to a friend
Privacy statement
News and Press Releases

The key to tackling drug development complexity: Collaboration.

Laupheim and Ravensburg, Germany, Milford, MA, and Skokie, IL, USA, July 6, 2020 – Vetter and Rentschler Biopharma, two globally operating Contract Development and Manufacturing Organizations (CDMOs), today announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. With drug development growing increasingly complex and cost-intensive, biopharmaceutical companies are under significant pressure to streamline their products’ path to market. The desired goal of the collaboration is to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
More info >>

White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement